Pariceract
Pariceract (LTI-291) is an activator of glucocerebrosidase (Gcase), with activation rates of more than 60% (1 μM) and between 10%-20% (0.1 μM) . Pariceract can be used for Parkinson's disease and endometriosis research[1].
Product Specifications
CAS Number
[1919820-28-2]
Product Name Alternative
LTI-291; BIA 28-6156
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Glycosidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Endocrinology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/LTI-291.html
Concentration
10mM
Purity
99.11
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=C2N=C(C)C=C(C)N2N=C1)N[C@@H]3CC[C@@H](OCCCCC)CC3
Molecular Formula
C20H30N4O2
Molecular Weight
358.48
Precautions
H302, H315, H319, H335
References & Citations
[1]Renato T. Skerlj, et al. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds. WO 2017192841 A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
